[{"orgOrder":0,"company":"VisiRose","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Rose Bengal Disodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VisiRose","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"VisiRose \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VisiRose \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by VisiRose

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : The financing is intended to support the clinical development of VisiRose’s formulated Rose Bengal Disodium for the treatment of infectious keratitis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 14, 2025

                          Lead Product(s) : Rose Bengal Disodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $3.0 million

                          Deal Type : Financing

                          blank